306 related articles for article (PubMed ID: 24337064)
21. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients.
Fagerlund B; Mackeprang T; Gade A; Glenthøj BY
CNS Spectr; 2004 May; 9(5):364-74. PubMed ID: 15115949
[TBL] [Abstract][Full Text] [Related]
22. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study.
Cazzullo CL; Sacchetti E; Galluzzo A; Panariello A; Adorni A; Pegoraro M; Bosis S; Colombo F; Trabattoni D; Zagliani A; Clerici M
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):33-9. PubMed ID: 11853116
[TBL] [Abstract][Full Text] [Related]
23. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
24. Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naïve first-episode schizophrenia.
Chen D; Li H; Zhao Q; Song J; Lin C; Yu J
Psychiatry Res; 2021 Mar; 297():113717. PubMed ID: 33503523
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Smith RC; Rachakonda S; Dwivedi S; Davis JM
Psychiatry Res; 2012 Oct; 199(3):159-63. PubMed ID: 22475524
[TBL] [Abstract][Full Text] [Related]
26. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers.
Singh S; Verma SK; Kumar S; Ahmad MK; Nischal A; Singh SK; Dixit RK
Immunol Lett; 2018 Apr; 196():1-10. PubMed ID: 29329680
[TBL] [Abstract][Full Text] [Related]
27. Pressure Injuries Treated With Anodal and Cathodal High-voltage Electrical Stimulation: the Effect on Blood Serum Concentration of Cytokines and Growth Factors in Patients With Neurological Injuries. A Randomized Clinical Study.
Polak A; Kloth LC; Paczula M; Nawrat-Szoltysik A; Kucio E; Manasar A; Blaszczak E; Janikowska G; Mazurek U; Malecki A; Kucio C
Wound Manag Prev; 2019 Nov; 65(11):19-32. PubMed ID: 31702992
[TBL] [Abstract][Full Text] [Related]
28. APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.
Song X; Li X; Gao J; Zhao J; Li Y; Fan X; Lv L
PLoS One; 2014; 9(4):e93902. PubMed ID: 24710015
[TBL] [Abstract][Full Text] [Related]
29. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
30. Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.
Noto C; Ota VK; Gouvea ES; Rizzo LB; Spindola LM; Honda PH; Cordeiro Q; Belangero SI; Bressan RA; Gadelha A; Maes M; Brietzke E
Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25522386
[TBL] [Abstract][Full Text] [Related]
31. Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine.
Ajami A; Abedian F; Hamzeh Hosseini S; Akbarian E; Alizadeh-Navaei R; Taghipour M
Iran J Immunol; 2014 Sep; 11(3):200-9. PubMed ID: 25265997
[TBL] [Abstract][Full Text] [Related]
32. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
33. Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.
de Witte L; Tomasik J; Schwarz E; Guest PC; Rahmoune H; Kahn RS; Bahn S
Schizophr Res; 2014 Apr; 154(1-3):23-9. PubMed ID: 24582037
[TBL] [Abstract][Full Text] [Related]
34. Effects of macular xanthophyll supplementation on brain-derived neurotrophic factor, pro-inflammatory cytokines, and cognitive performance.
Stringham NT; Holmes PV; Stringham JM
Physiol Behav; 2019 Nov; 211():112650. PubMed ID: 31425700
[TBL] [Abstract][Full Text] [Related]
35. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
Saddichha S; Manjunatha N; Ameen S; Akhtar S
J Clin Psychiatry; 2007 Nov; 68(11):1793-8. PubMed ID: 18052574
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year.
Sanz-Fuentenebro J; Taboada D; Palomo T; Aragües M; Ovejero S; Del Alamo C; Molina V
Schizophr Res; 2013 Sep; 149(1-3):156-61. PubMed ID: 23870807
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
[TBL] [Abstract][Full Text] [Related]
38. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Meyer JM; Mao Y; Pikalov A; Cucchiaro J; Loebel A
Int Clin Psychopharmacol; 2015 Nov; 30(6):342-50. PubMed ID: 26196189
[TBL] [Abstract][Full Text] [Related]
39. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
40. Effect of risperidone on serum cytokines.
Kim DJ; Kim W; Yoon SJ; Go HJ; Choi BM; Jun TY; Kim YK
Int J Neurosci; 2001; 111(1-2):11-9. PubMed ID: 11913333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
